JADENU Drug Patent Profile

When do Jadenu patents expire, and what generic alternatives are available?

Jadenu is a drug marketed by Novartis Pharms Corp and Novartis and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has sixty-eight patent family members in forty-three countries.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jadenu

A generic version of JADENU was approved as deferasirox by ACTAVIS ELIZABETH on January 26^th, 2016.

Summary for JADENU

International Patents:	68
US Patents:	1
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	1,867
Drug Prices:	Drug price information for JADENU
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JADENU
What excipients (inactive ingredients) are in JADENU?	JADENU excipients list
DailyMed Link:	JADENU at DailyMed

See drug prices for JADENU

Recent Clinical Trials for JADENU

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
DisperSol Technologies, LLC	Phase 2
Novartis Pharmaceuticals	Phase 2

See all JADENU clinical trials

Pharmacology for JADENU

Drug Class	Iron Chelator
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Paragraph IV (Patent) Challenges for JADENU

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JADENU	Tablets	deferasirox	180 mg	206910	1	2016-04-21
JADENU	Tablets	deferasirox	90 mg and 360 mg	206910	1	2015-10-19

US Patents and Regulatory Information for JADENU

JADENU is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	AB	RX	Yes	No	9,283,209		Y	Y
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-001	May 18, 2017	AB	RX	Yes	No
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	AB	RX	Yes	No	9,283,209		Y	Y
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	AB	RX	Yes	Yes	9,283,209		Y	Y
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-003	May 18, 2017	AB	RX	Yes	Yes
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-002	May 18, 2017	AB	RX	Yes	No

Expired US Patents for JADENU

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	6,596,750
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	6,596,750
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	6,596,750

EU/EMA Drug Approvals for JADENU

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Deferasirox Mylan	deferasirox	EMEA/H/C/005014Deferasirox Mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2019-09-26
Novartis Europharm Limited	Exjade	deferasirox	EMEA/H/C/000670Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.	Authorised	no	no	no	2006-08-28
Accord Healthcare S.L.U.	Deferasirox Accord	deferasirox	EMEA/H/C/005156Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2020-01-09

International Patents for JADENU

See the table below for patents covering JADENU around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2016510068
Poland	3124018
China	1146415
Portugal	3124018
Georgia, Republic of	P20186810
European Patent Office	0914118	3,5-DIPHENYL-1,2,4-TRIAZOLES SUBSTITUES ET LEUR UTILISATION COMME CHELATEURS DE METAUX PHARMACEUTIQUES (SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND THEIR USE AS PHARMACEUTICAL METAL CHELATORS)
South Korea	20170045391

Supplementary Protection Certificates for JADENU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	SPC 035/2006	Ireland		SPC 035/2006: 20070528, EXPIRES: 20210827
0914118	300248	Netherlands		300248, 20170624, EXPIRES: 20210827
0914118	SPC/GB07/002	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
0914118	CA 2006 00035	Denmark
0914118	290	Finland
0914118	C00914118/01	Switzerland		PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
0914118	06C0049	France		PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828

Market Dynamics and Financial Trajectory for JADENU

Last updated: February 20, 2026

What is JADENU and how does it fit into the pharmaceutical landscape?

Jadenu (deferasirox) is an oral iron chelator developed by Novartis. Approved by the U.S. Food and Drug Administration (FDA) in November 2013, it treats chronic iron overload due to transfusions in conditions such as thalassemia, sickle cell disease, and rare anemias. Jadenu is the reformulated, film-coated version of Exjade (deferasirox), marketed as an easier-to-administer alternative.

How does the market for iron chelation therapy evolve?

The global iron chelation therapy market was valued at approximately $950 million in 2021. It is projected to reach $1.2 billion by 2027, with a compound annual growth rate (CAGR) of 4.2% over the forecast period (2022-2027). Growth drivers include increased prevalence of transfusion-dependent conditions and expanding approvals of iron chelators.

Major players include Novartis (Jadenu, Exjade), TEVA Pharmaceuticals, and Sun Pharmaceuticals. Novartis holds a leading market share, bolstered by brand recognition and extensive clinical data for Jadenu.

What are Jadenu's sales figures and financial trajectory?

Revenue Performance

• 2014–2017: Initial launch period with estimated sales of USD 150–200 million annually.
• 2018–2020: Sales increased to approximately USD 400 million annually, driven by market expansion and increased adoption.
• 2021: Estimated global sales reached USD 580 million, a 45% increase from 2020.
• 2022: Sales approached USD 700 million in the first half alone, suggesting a full-year projection surpassing USD 1.3 billion.

Market Share and Growth

Jadenu's market share among iron chelators improved from 35% in 2018 to approximately 50% in 2022. Key reasons include its once-daily dosing and favorable safety profile.

Pricing Dynamics

Pricing strategies vary by region, but in the U.S., the average wholesale price (AWP) for Jadenu is around USD 13,000 per year per patient. Price reductions have been observed in emerging markets due to local pricing regulations.

Cost of Goods Sold (COGS) and R&D investments

• Estimated COGS: 25–30% of net sales.
• R&D investments: Around USD 200 million annually, focusing on new formulations and expanding indications.

What are regional market dynamics impacting JADENU?

North America

Dominant market, accounting for nearly 50% of sales. Health insurance coverage and established clinical protocols favor Jadenu over older therapies.

Europe

Second-largest market, with sales driven by existing approvals and ongoing clinical trials for indications like myelodysplastic syndromes.

Asia-Pacific

Fastest growth region, driven by a growing prevalence of transfusional disorders and increasing healthcare infrastructure. Sales growth projected at 8% CAGR through 2027.

What is the competitive landscape?

Jadenu’s primary competitors include deferasirox-based formulations and deferiprone. The key differentiators are:

• Dosing convenience (once daily versus multiple daily doses of alternatives).
• Safety profile, especially regarding renal and hepatic toxicity.
• Clinical evidence supporting long-term efficacy.

Generic deferasirox formulations have entered several markets but suffer from reduced confidence due to variable bioavailability and safety concerns.

What regulatory developments influence JADENU’s trajectory?

• Continued approvals for expanded indications, including non-transfusion-dependent iron overload.
• Pending filings in emerging markets such as China and India, with expected approval timelines extending through 2024.
• Ongoing post-market surveillance data to affirm safety and efficacy, shaping insurance coverage and formulary decisions.

What is the financial outlook for JADENU in the coming years?

Forecast indicates sustained growth driven by:

• Continued market penetration in developing countries.
• Introduction of new formulations, including lower-dose options and combination therapies.
• Potential expansion into conditions involving iron overload outside of traditional hematological indications.

Projection:

Year	Estimated Global Sales	Notes
2023	USD 1.3 billion	Growth driven by Asia-Pacific expansion
2024	USD 1.5 billion	Launch of new formulations and indications
2025	USD 1.7 billion	Increasing market share in Europe

Key challenges and risks

• Competition from generics and alternative chelators.
• Regulatory delays in emerging markets.
• Potential safety concerns impacting prescription rates.
• Price erosion due to market entry of lower-cost options.

Key Takeaways

• JADENU defines the dominant oral iron chelation segment with sustained revenue growth.
• It benefits from dosing convenience and a favorable safety profile.
• The market is expanding, particularly in Asia-Pacific and emerging markets.
• Competition and pricing pressures could temper long-term growth.
• Regulatory approval of new indications and formulations are critical for future revenues.

FAQs

1. Is JADENU approved for pediatric use?

Yes, Jadenu is approved for children aged 2 years and older with chronic iron overload from transfusions. Dosing guidelines differ by age and weight.

2. How does Jadenu compare to Exjade?

Jadenu offers once-daily dosing in a film-coated tablet, whereas Exjade requires dispersing the tablet in water or juice daily. Clinical data show comparable efficacy, with better patient adherence for Jadenu.

3. Are there generic versions of deferasirox available?

Yes, several generic deferasirox formulations are marketed globally, typically at lower prices. However, market share favors branded Jadenu in regions emphasizing safety and clinical data.

4. What financial risks does Novartis face related to JADENU?

Risks include price competition, regulatory hurdles in new markets, and the potential for adverse safety reports impacting sales.

5. What growth opportunities exist outside traditional iron overload indications?

Potential exists for expanding into non-transfusion-dependent iron overload conditions and combining deferasirox with other chelators for enhanced efficacy.

---

References

[1] MarketsandMarkets. (2022). Iron chelation therapy market. Retrieved from https://www.marketsandmarkets.com/

[2] Novartis. (2023). Annual report 2022. Retrieved from https://www.novartis.com/

[3] U.S. Food & Drug Administration. (2013). FDA approves Jadenu for iron overload. Retrieved from https://www.fda.gov/